{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-326119","form_type":"8-K","ticker":"FLGT","cik":"0001674930","company_name":"Fulgent Genetics, Inc.","filed_at":"2026-07-30T20:09:36+00:00","discovered_at":"2026-07-30T20:11:00.296693+00:00","generated_at":"2026-07-30T20:11:47.762002+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Fulgent Genetics Q2 2026 revenue $85.4M, GAAP loss $1.05/share, revises FY revenue guidance to $330-340M","bullets":["Revenue of $85.4M, up 20.1% sequentially; GAAP gross margin 30.1%.","GAAP net loss $29.5M ($1.05 loss per share); non-GAAP loss $16.2M ($0.58 loss per share).","Repurchased 1.5M shares for $23.8M in Q2 2026.","Cash and investments $551.5M plus anticipated tax refund of ~$106.1M.","Revised annual revenue guidance to $330-340M from prior range (not disclosed)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-326119","json":"https://secwatch.observer/filing/0001193125-26-326119.json","markdown":"https://secwatch.observer/filing/0001193125-26-326119.md","text":"https://secwatch.observer/filing/0001193125-26-326119.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1674930/000119312526326119/0001193125-26-326119-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1674930/000119312526326119/flgt-20260730.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-30T20:11:47.762002+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}